<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="99281">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT02093858</url>
  </required_header>
  <id_info>
    <org_study_id>RRW</org_study_id>
    <nct_id>NCT02093858</nct_id>
  </id_info>
  <brief_title>The Mechanism of TCF7L2 and SLC30A8 on Antipsychotic-induced Metabolic Syndrome</brief_title>
  <official_title>The Mechanism of TCF7L2 and SLC30A8 on Antipsychotic-induced Metabolic Syndrome</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Central South University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Central South University</source>
  <oversight_info>
    <authority>China: Food and Drug Administration</authority>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Almost all of antipsychotics can induce metabolic syndrome,Genetic factors play a key role
      in the development of metabolic syndrome,TCF7L2 and SLC30A8 are strongestly correlated with
      metabolic syndrome.Moreover,Antipsychotics have an effect on the expression of TCF7L2 and
      SLC30A8 genes.It indicates the variations of TCF7L2 and SLC30A8 play an important part in
      the development of antipsychotics-induced metabolic syndrome.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      -  In this study, we will determine the effect of olanzapine on the expression of TCF7L2
           and SLC30A8.

        -  The relationship of the polymorphism of TCF7L2 and SLC30A8 with antipsychotic-induced
           metabolic syndrome in schizophrenia patients.
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date>April 2014</start_date>
  <completion_date type="Anticipated">December 2017</completion_date>
  <primary_completion_date type="Anticipated">December 2017</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Observational</study_type>
  <study_design>Observational Model: Case-Only, Time Perspective: Prospective</study_design>
  <primary_outcome>
    <measure>Change in weight and blood glucose</measure>
    <time_frame>24 weeks</time_frame>
    <safety_issue>Yes</safety_issue>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change of the blood pressure and blood lipid</measure>
    <time_frame>24 weeks</time_frame>
    <safety_issue>Yes</safety_issue>
  </secondary_outcome>
  <other_outcome>
    <measure>Change of serum insulin</measure>
    <time_frame>24 weeks</time_frame>
    <safety_issue>No</safety_issue>
  </other_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">212</enrollment>
  <condition>Schizophrenia</condition>
  <condition>Metabolic Syndrome</condition>
  <arm_group>
    <arm_group_label>olanzapine</arm_group_label>
    <description>15-25mg/day for 24 weeks</description>
  </arm_group>
  <eligibility>
    <study_pop>
      <textblock>
        All participants met the Diagnostic and Statistical Manual of Mental Disorder-Fourth
        Edition (DSM-IV) criteria for first episode schizophrenia.All of the patients and their
        familier are know of the study and sign the informed consent.
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Clinical diagnosis of first episode schizophrenia

          -  Must be able to swallow tablets

          -  Take only one antipsychotics

        Exclusion Criteria:

          -  liver or renal  or cardiovascular diseases

          -  pregnant or lactating women

          -  drug and alcohol dependence
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Wu R Rong, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Central South University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>RenRong Wu, PhD</last_name>
    <phone>0731-85554052</phone>
    <email>wurenrong2013@163.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Mental Health Institute</name>
      <address>
        <city>Changsha</city>
        <state>Hunan</state>
        <zip>410011</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Renrong Wu, PhD</last_name>
      <phone>86-15874179855</phone>
      <email>wurenrong2013@163.com.cn</email>
    </contact>
    <investigator>
      <last_name>Renrong Wu, Doctor</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>March 2014</verification_date>
  <lastchanged_date>March 20, 2014</lastchanged_date>
  <firstreceived_date>March 20, 2014</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Central South University</investigator_affiliation>
    <investigator_full_name>Renrong Wu</investigator_full_name>
    <investigator_title>PhD</investigator_title>
  </responsible_party>
  <keyword>Metabolic Syndrome</keyword>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Schizophrenia</mesh_term>
    <mesh_term>Metabolic Syndrome X</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Antipsychotic Agents</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
